<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02100514</url>
  </required_header>
  <id_info>
    <org_study_id>B1481045</org_study_id>
    <secondary_id>SPIRE-LL</secondary_id>
    <secondary_id>2014-000478-20</secondary_id>
    <nct_id>NCT02100514</nct_id>
  </id_info>
  <brief_title>Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events</brief_title>
  <acronym>SPIRE-LL</acronym>
  <official_title>A 52 Week Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter, double-blind, randomized study to access the efficacy, safety
      and tolerability of Bococizumab (PF-04950615; RN316) in subjects with hyperlipidemia
      receiving background statin therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 28, 2014</start_date>
  <completion_date type="Actual">July 10, 2017</completion_date>
  <primary_completion_date type="Actual">July 15, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Fasting Total Cholesterol (TC) at Week 12, 24 and 52</measure>
    <time_frame>Baseline, Week 12, 24, 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) at Week 12, 24 and 52</measure>
    <time_frame>Baseline, Week 12, 24, 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Fasting Non High Density Lipoprotein Cholesterol (Non HDL-C) at Week 12, 24 and 52</measure>
    <time_frame>Baseline, Week 12, 24, 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) by Triglycerides Cut-off of Less Than (&lt;) 200 Milligram Per Deciliter (mg/dL) at Week 12, 24 and 52</measure>
    <time_frame>Baseline, Week 12, 24, 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) by Triglycerides Cut-off of Greater Than or Equal to (&gt;=) 200 Milligram Per Deciliter (mg/dL) at Week 12, 24 and 52</measure>
    <time_frame>Baseline, Week 12, 24, 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Fasting Lipoprotein (A) (Lp[A]) at Week 12, 24 and 52</measure>
    <time_frame>Baseline, Week 12, 24, 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL-C) at Week 12, 24 and 52</measure>
    <time_frame>Baseline, Week 12, 24, 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 24 and 52</measure>
    <time_frame>Baseline, Week 24, 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Fasting Triglycerides (TG) at Week 12, 24 and 52</measure>
    <time_frame>Baseline, Week 12, 24, 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Fasting Apolipoprotein A-I (ApoA-I) at Week 12, 24 and 52</measure>
    <time_frame>Baseline, Week 12, 24, 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Fasting Apolipoprotein A-II (ApoA-II) at Week 12, 24 and 52</measure>
    <time_frame>Baseline, Week 12, 24, 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Fasting Very Low Density Lipoprotein Cholesterol (VLDL-C) at Week 12, 24 and 52</measure>
    <time_frame>Baseline, Week 12, 24, 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) by Triglycerides Cut-off of Less Than (&lt;) 200 Milligram Per Deciliter (mg/dL) at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) by Triglycerides Cut-off of Greater Than or Equal to (&gt;=) 200 Milligram Per Deciliter (mg/dL) at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Fasting Total Cholesterol (TC) at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Fasting Non High Density Lipoprotein Cholesterol (Non HDL-C) at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Fasting Apolipoprotein B (ApoB) at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Fasting Lipoprotein (A) (Lp[A]) at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL-C) at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Ratio of Fasting Total Cholesterol (TC) to High Density Lipoprotein Cholesterol (HDL-C) at Week 12, 24 and 52</measure>
    <time_frame>Baseline, Week 12, 24, 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Ratio of Fasting Apolipoprotein B (ApoB) to Apolipoprotein A-I (ApoA-I) at Week 12, 24 and 52</measure>
    <time_frame>Baseline, Week 12, 24, 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Fasting Low Density Lipoprotein Cholesterol (LDL-C) Less Than or Equal to (&lt;=) 100 Milligram Per Deciliter (mg/dL) at Week 12, 24 and 52</measure>
    <time_frame>Week 12, 24, 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Fasting Low Density Lipoprotein Cholesterol (LDL-C) Less Than or Equal to (&lt;=) 70 Milligram Per Deciliter (mg/dL) at Week 12, 24 and 52</measure>
    <time_frame>Week 12, 24, 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration Versus Time Summary of PF-04950615</measure>
    <time_frame>Week 12, 24, 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs) Related to Type 1 and 3 Hypersensitivity Reactions and Injection Site Reactions</measure>
    <time_frame>Baseline up to end of study (up to 58 weeks)</time_frame>
    <description>Type 1 hypersensitivity or allergic reactions were possible in response to any injected protein and included shortness of breath, urticaria, anaphylaxis and angioedema. Type 3 hypersensitivity reactions were similar to Type 1 hypersensitivity reactions but were likely to be delayed from the time of injection and included symptoms such as rash, urticaria, polyarthritis, myalgia's, polysynovitis, fever and if severe then included glomerulonephritis. Injection site reactions included injection site bruising, discolouration, erythema, haematoma, haemorrhage, nodule, induration, inflammation, mass, pain, paraesthesia, pruritus, swelling, vesicles, warmth, scab and rash. Participants with type 1 or type 3 hypersensitivity reactions and participants with injection site reactions were reported in this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Positive Anti-drug Antibodies (ADA) of PF-04950615</measure>
    <time_frame>Baseline up to end of study (up to 58 weeks)</time_frame>
    <description>Percentage of participants with at least 1 positive ADA titer were reported. Participants with their ADA titer &gt;=6.23 were considered to be ADA positive.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">750</enrollment>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Bococizumab (PF-04950615; RN316)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bococizumab (PF-04950615; RN316)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bococizumab (PF-04950615; RN316)</intervention_name>
    <description>150 mg every 2 weeks, subcutaneous injection for 52 weeks.</description>
    <arm_group_label>Bococizumab (PF-04950615; RN316)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous injection every 2 weeks for 52 weeks.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treated with a statin

          -  Fasting LDL-C &gt;=100 mg/dL and triglyceride &lt;= 400 mg/dL

          -  High or very high risk of incurring a cardiovascular event

        Exclusion Criteria:

          -  Pregnant or breastfeeding females

          -  Cardiovascular or cerebrovascular event or procedure within 90 days

          -  Congestive heart failure NYHA class IV

          -  Poorly controlled hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Advanced Cardiovascular, LLC Research</name>
      <address>
        <city>Alexander City</city>
        <state>Alabama</state>
        <zip>35010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Cardiovascular, LLC, Research</name>
      <address>
        <city>Auburn</city>
        <state>Alabama</state>
        <zip>36830</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc./Family Practice Specialists, Ltd.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc./Family Practice Specialists, LTD</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Institute of the Ozarks</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Office of Larry Watkins, MD</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Institute of Research</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>lntermed Group</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMD Medical Group</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Office of Lucita M. Cruz, M.D., Inc.</name>
      <address>
        <city>Norwalk</city>
        <state>California</state>
        <zip>90650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Superior Research, LLC</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Superior Research ,LLC</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95831</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orange County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ventura Clinical Trials</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc. / Colorado Springs Family Practice</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Creekside Endocrine Associates, PC</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boca Raton Clinical Research Associates</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BRCR Medical Center, Inc.</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <zip>34601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linfritz Research Institute Inc.</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Health Center</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Care Family Rehab &amp; Research Center</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indago Research &amp; Health Center, Inc.</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NewPhase Clinical Trials, Corp.</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Panax Clinical Research</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precision Research Organization</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunrise Research Institute, Inc</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prestige Clinical Research Center, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suncoast Research Group, LLD</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elite Clinical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Research Specialists of Florida, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbus Clinical Services, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Quality</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Family Medical</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renstar Medical Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andres Patron, D.O.P.A.</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pines Care Research Center, LLC</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DBC Research USA</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Progressive Medical Research</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accord Clinical Research, Llc</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Coast Institute for Research, LLC/ Baker-Gilmour Cardiovascular Institute</name>
      <address>
        <city>Saint Augustine</city>
        <state>Florida</state>
        <zip>32086</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Coast Institute for RSCH, St. Augustine Cardiology Associates, Research</name>
      <address>
        <city>Saint Augustine</city>
        <state>Florida</state>
        <zip>32086</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Center of Sarasota</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33634</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Trials, Inc.</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Health Network of Indiana, LLC</name>
      <address>
        <city>Avon</city>
        <state>Indiana</state>
        <zip>46123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC</name>
      <address>
        <city>Augusta</city>
        <state>Kansas</state>
        <zip>67010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Family Physicians</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial Health, LLP</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crescent City Clinical Research Center, LLC</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of America LA</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bethesda Health Research</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>208174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centennial Medical Group</name>
      <address>
        <city>Elkridge</city>
        <state>Maryland</state>
        <zip>21075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McLaren Flint</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CentraCare Heart &amp; Vascular Center @ St. Cloud Hospital</name>
      <address>
        <city>Saint Cloud</city>
        <state>Minnesota</state>
        <zip>56303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CentraCare Heart &amp; Vascular Center at St. Cloud Hospital</name>
      <address>
        <city>Saint Cloud</city>
        <state>Minnesota</state>
        <zip>56303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riser Medical Research</name>
      <address>
        <city>Picayune</city>
        <state>Mississippi</state>
        <zip>39466</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University, The Center for Advanced Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc. (Prairie Fields Family Medicine, PC)</name>
      <address>
        <city>Fremont</city>
        <state>Nebraska</state>
        <zip>68025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ActivMed Practices &amp; Research, Inc.</name>
      <address>
        <city>Portsmouth</city>
        <state>New Hampshire</state>
        <zip>03801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albuquerque Clinical Trials, Inc.</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physician's East Endocrinology</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physician's East P.A.</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physician's East, PA</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catawba Valley Medical Group, Inc.</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of America, Inc.</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Hickory</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Internal Medicine Consultants, Inc.</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primed Clinical Research</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45419</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Daniel G. Williams, MD</name>
      <address>
        <city>Perrysburg</city>
        <state>Ohio</state>
        <zip>43551</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Oklahoma Heart Research, LLC</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Castlerock Clinical Research Consultants,LLC</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harleysville Medical Associates</name>
      <address>
        <city>Harleysville</city>
        <state>Pennsylvania</state>
        <zip>19438</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Berks Cardiologists, Ltd.</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research South, LLC</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ellipsis Research Group, LLC</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spartanburg Medical Research</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stern Cardiovascular Foundation, Inc</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apex Cardiology</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Associates of Jackson</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research, Inc d/b/a PMG Research of Knoxville</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Punzi Medical Center</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juno Research, LLC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gulf Coast Medical Research,LLC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Michelle Zaniewski MD., PA.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juno Research, LLC</name>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <zip>77450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gulf Coast Medical Research, LLC</name>
      <address>
        <city>Missouri City</city>
        <state>Texas</state>
        <zip>77459</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc./ Plano Internal Medicine Associates</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gulf Coast Medical Research, LLC</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aspen Clinical Research</name>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <zip>84058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Millennium Clinical Trials, LLC</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <zip>22207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Clinical Research-Norfolk, Inc.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sound Health Care Center</name>
      <address>
        <city>Port Orchard</city>
        <state>Washington</state>
        <zip>98366</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sound Medical Research</name>
      <address>
        <city>Port Orchard</city>
        <state>Washington</state>
        <zip>98366</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walla Walla Clinic</name>
      <address>
        <city>Walla Walla</city>
        <state>Washington</state>
        <zip>99362</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigation Specialists, Inc.</name>
      <address>
        <city>Kenosha</city>
        <state>Wisconsin</state>
        <zip>53142</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HFM Heart and Vascular Center/Holy Family Memorial, Inc</name>
      <address>
        <city>Manitowoc</city>
        <state>Wisconsin</state>
        <zip>54220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMC Clinical Research Inc. (Calgary)</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2H 2G4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Dr. Ronald Collette MD</name>
      <address>
        <city>Burnaby</city>
        <state>British Columbia</state>
        <zip>V5G 1T4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Arts Health Research Group</name>
      <address>
        <city>Kamloops</city>
        <state>British Columbia</state>
        <zip>V2C 1K7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Medical Arts Health Research Group</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 1V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glover Medical Clinic</name>
      <address>
        <city>Langley</city>
        <state>British Columbia</state>
        <zip>V3A 4H9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fraser Clinical Trials</name>
      <address>
        <city>New Westminster</city>
        <state>British Columbia</state>
        <zip>V3L 3W4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Medical Arts Health Research Group</name>
      <address>
        <city>Penticton</city>
        <state>British Columbia</state>
        <zip>V2A 5C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Office of James K. Lai, MD Inc.</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1K3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook Street Medical Clinic</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8V 4A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMC Clinical Research Inc. (Barrie)</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 7G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMC Clinical Research Inc. (Brampton)</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6S 0C9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aggarwal And Associates Ltd</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6T 0G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corunna Medical Research Centre</name>
      <address>
        <city>Corunna</city>
        <state>Ontario</state>
        <zip>N0N 1G0</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMC Clinical Research Inc. (Etobicoke)</name>
      <address>
        <city>Etobicoke</city>
        <state>Ontario</state>
        <zip>M9R 4E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMC Clinical Research Inc. (Markham)</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L6B 0P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SKDS Research Inc.</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMC Clinical Research Inc. (Oakville)</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6M 1M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Office of Dr. James Cha</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1J 2K1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kawartha Cardiology Clinical Trials</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 0B2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scarborough Cardiology Research</name>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <zip>M1E 5E9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMC Clinical Research Inc. (Thornhill)</name>
      <address>
        <city>Thornhill</city>
        <state>Ontario</state>
        <zip>L4J 8L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rouge Valley Health System - Centenary</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M1E 4B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMC Clinical Research Inc. (Bayview)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4G 3E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manna Research Inc.</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9W 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ecogene-21</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H 7K9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ViaCar Recherche Clinique Inc.</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Depistage et de Recherche Cardiovasculaire Rive-Sud</name>
      <address>
        <city>Longueuil</city>
        <state>Quebec</state>
        <zip>J4M2X1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre De Sante Et De Services Sociaux De Beauce (CSSSB)</name>
      <address>
        <city>Saint-Georges, Beauce</city>
        <state>Quebec</state>
        <zip>G5Y 4T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.I.C. Maurice Inc.</name>
      <address>
        <city>Trois-Rivieres</city>
        <state>Quebec</state>
        <zip>G8T 7A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.I.C. Mauricie Inc.</name>
      <address>
        <city>Trois-Rivieres</city>
        <state>Quebec</state>
        <zip>G8T 7A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique des maladies lipidiques de Quebec</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4W2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alpha Recherche Clinique</name>
      <address>
        <city>Quebec</city>
        <zip>G3K 2P8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kardiologicka ambulance</name>
      <address>
        <city>Trutnov</city>
        <state>Kralovehradecky KRAJ</state>
        <zip>54101</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice Kralovske Vinohrady, II. interni klinika</name>
      <address>
        <city>Praha 10</city>
        <state>Vinohrady</state>
        <zip>100 34</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice u sv. Anny Brno. Oddeleni klinicke biochemie</name>
      <address>
        <city>Brno</city>
        <zip>656 91</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice u sv. Anny. Nemoenicni lekarna (pharmacy)</name>
      <address>
        <city>Brno</city>
        <zip>656 91</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiocentrum Kladno s.r.o., Kardiologicka ambulance</name>
      <address>
        <city>Kladno</city>
        <zip>27280</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lekarna - P-P Klinika Kladno</name>
      <address>
        <city>Kladno</city>
        <zip>27280</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lunacor s.r.o.</name>
      <address>
        <city>Kromeriz</city>
        <zip>76701</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice Olomouc, III. interni klinika  nefrologicka, revmatologicka a endokrinologicka</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lekarna Fakultni nemocnice Olomouc (pharmacy)</name>
      <address>
        <city>Olomouc</city>
        <zip>77520</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lekarna Domovina</name>
      <address>
        <city>Olomouc</city>
        <zip>779 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PreventaMed, s.r.o.</name>
      <address>
        <city>Olomouc</city>
        <zip>779 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IKEM, Oddeleni preventivni kardiologie</name>
      <address>
        <city>Praha 4</city>
        <zip>140 21</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IKEM, Ustavni lekarna</name>
      <address>
        <city>Praha 4</city>
        <zip>140 21</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENU lekarna</name>
      <address>
        <city>Pribram</city>
        <zip>261 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kardiologicka ambulance, III. Poliklinika</name>
      <address>
        <city>Pribram</city>
        <zip>261 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lekarna 203-02</name>
      <address>
        <city>Slany</city>
        <zip>274 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Slany, Interni oddeleni</name>
      <address>
        <city>Slany</city>
        <zip>274 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AeskuLab k.s., Lipidova poradna</name>
      <address>
        <city>Teplice</city>
        <zip>415 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lekarna Centrum (pharmacy)</name>
      <address>
        <city>Teplice</city>
        <zip>415 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr.Max lekarna</name>
      <address>
        <city>Trutnov</city>
        <zip>541 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Etela-Karjalan Keskussairaala</name>
      <address>
        <city>Lappeenranta</city>
        <zip>53130</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sacred Heart Hospital-Hallym University</name>
      <address>
        <city>Anyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>431-796</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanyang University Guri Hospital</name>
      <address>
        <city>Guri-si</city>
        <state>Gyeonggi-do</state>
        <zip>11923</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dong-A University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>49201</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <state>ER</state>
        <zip>7513</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Lucas Andreas Hospital</name>
      <address>
        <city>Amsterdam</city>
        <state>North Holland</state>
        <zip>1061 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gelre Hospitals</name>
      <address>
        <city>Apeldoorn</city>
        <zip>7334 DZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andromed Eindhoven</name>
      <address>
        <city>Eindhoven</city>
        <zip>5611 NV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <zip>7513 ER</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beatrix Hospital</name>
      <address>
        <city>Gorinchem</city>
        <zip>4204 AA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martini Ziekenhuis</name>
      <address>
        <city>Groningen</city>
        <zip>9728 NT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zuyderland Medisch Centrum</name>
      <address>
        <city>Heerlen</city>
        <zip>6419 PC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andro Medical Research B.V.</name>
      <address>
        <city>Rotterdam</city>
        <zip>3021 HC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ikazia Hospital</name>
      <address>
        <city>Rotterdam</city>
        <zip>3083AN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>D&amp;A Research and Genetics</name>
      <address>
        <city>Sneek</city>
        <zip>8601 ZR</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elisabeth Hospital</name>
      <address>
        <city>Tilburg</city>
        <zip>5022 GC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ossum Gronert Legetjeneste AS</name>
      <address>
        <city>Honefoss</city>
        <zip>3515</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo Universitetssykehus HF</name>
      <address>
        <city>Oslo</city>
        <zip>0373</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo Universitetssykehus HF, Ulleval</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KO-MED Centra Kliniczne Lublin</name>
      <address>
        <city>Lublin</city>
        <state>Lubelskie</state>
        <zip>20-362</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KO-MED Centra Kliniczne Zamosc</name>
      <address>
        <city>Zamosc</city>
        <state>Lubelskie</state>
        <zip>22-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KO-MED. Centra Kliniczne Staszow</name>
      <address>
        <city>Staszow</city>
        <state>Swietokrzyskie</state>
        <zip>28-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Sp. z o.o. Oddzial w Gdyni</name>
      <address>
        <city>Gdynia</city>
        <zip>81-384</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MCBK Sc lwona Czajkowska Monika Barney</name>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <zip>05-825</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Sp. z o. o. Oddizial w Katowicach.</name>
      <address>
        <city>Katowice</city>
        <zip>40-040</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinport Tura Lipinska Dabrowski S.C.</name>
      <address>
        <city>Katowice</city>
        <zip>40-084</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krakowski Szpital Specjalistyczny im. Jana Pawla II</name>
      <address>
        <city>Krakow</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jan Zbigniew Peruga NZOZ SALUS</name>
      <address>
        <city>Lodz</city>
        <zip>91-302</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zespol Opieki Zdrowotnej W Olawie, Oddzial Chorob Wewnetrznych</name>
      <address>
        <city>Olawa</city>
        <zip>55-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Sp. z o.o Oddzial w Poznaniu</name>
      <address>
        <city>Poznan</city>
        <zip>60-702</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KO-MED Centra Kliniczne Sp. z o.o.</name>
      <address>
        <city>Pulawy</city>
        <zip>24-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Sp. z o.o. Oddzial w Warszawie</name>
      <address>
        <city>Warszawa</city>
        <zip>01-192</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Sp. z o.o. Oddzial we Wroclawiu</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-088</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>.WroMedica Irena Bielicka, Janusz Szczepanik Spolka Cywlina</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-685</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ponce School Of Medicine</name>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiometabolic Research Center, Inc</name>
      <address>
        <city>Ponce</city>
        <zip>00717</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caparra Internal Medicine</name>
      <address>
        <city>Rio Grande</city>
        <zip>00745</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Heart Centre Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>169609</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Center (CTC)/Centrum foer klinisk proevning</name>
      <address>
        <city>Goteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vardcentralen Lessebo</name>
      <address>
        <city>Lessebo</city>
        <zip>360 50</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Consultants AB</name>
      <address>
        <city>Linkoping</city>
        <zip>58758</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ProbarE i Lund AB</name>
      <address>
        <city>Lund</city>
        <zip>222 22</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capio Citykliniken Hjartmottagning</name>
      <address>
        <city>Lund</city>
        <zip>22221</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dalecarlia Clinical Research Center</name>
      <address>
        <city>Rattvik</city>
        <zip>79530</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Citydiabetes</name>
      <address>
        <city>Stockholm</city>
        <zip>111 57</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset Huddinge</name>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Thames Valley Clinical Research Centre</name>
      <address>
        <city>Reading</city>
        <state>Berkshire</state>
        <zip>RG2 0TG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salford Royal NHS Foundation Trust</name>
      <address>
        <city>Salford</city>
        <state>Greater Manchester</state>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Scotland Clinical Research Centre</name>
      <address>
        <city>Glasgow</city>
        <state>Lanarkshire Scotland</state>
        <zip>G20 0SP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Lancashire Clinical Research Centre</name>
      <address>
        <city>Chorley</city>
        <state>Lancashire</state>
        <zip>PR7 7NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus North East Clinical Research Centre - Hexham General Hospital</name>
      <address>
        <city>Hexham</city>
        <state>Northumberland</state>
        <zip>NE46 1QJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Worcestershire Acute Hospitals NHS Trust - Worcestershire Royal Hospital</name>
      <address>
        <city>Worcester</city>
        <state>Worcestershire</state>
        <zip>WR5 1DD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Ayr - Nhs Ayrshire And Arran</name>
      <address>
        <city>Ayr</city>
        <zip>KA6 6DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Midlands Clinical Research Centre</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2SQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hull and East Yorkshire Hospitals NHS Trust</name>
      <address>
        <city>Hull</city>
        <zip>HU3 2JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Merseyside Clinical Research Centre</name>
      <address>
        <city>Liverpool</city>
        <zip>L22 0LG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Manchester Clinical Research Centre</name>
      <address>
        <city>Manchester</city>
        <zip>M15 6SX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abertawe Bro Morgannwg University Local Health Board Joint Clinical Research Facility,</name>
      <address>
        <city>Swansea</city>
        <zip>SA2 8PP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Finland</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Singapore</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1481045&amp;StudyName=Randomized%20Clinical%20Trial%20of%20RN316%20%28PF-04950615%29%20inSubjects%20With%20Primary%20Hyperlipidemia%20or%20Mixed%20Dyslipidemia%20At%20Risk%20Of%20Cardiovascular%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2014</study_first_submitted>
  <study_first_submitted_qc>March 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2014</study_first_posted>
  <results_first_submitted>June 23, 2017</results_first_submitted>
  <results_first_submitted_qc>June 23, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 21, 2017</results_first_posted>
  <last_update_submitted>February 9, 2018</last_update_submitted>
  <last_update_submitted_qc>February 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary hyperlipidemia or mixed dyslipidemia</keyword>
  <keyword>high risk of cardiovascular events</keyword>
  <keyword>multiple cardiovascular disease risk factors.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This study was conducted at multiple sites from 28 October 2014 to 15 July 2016.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received placebo matched to Bococizumab (PF-04950615) subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Bococizumab (PF-04950615) 150 Milligram (mg)</title>
          <description>Participants received PF-04950615 150 mg subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="247"/>
                <participants group_id="P2" count="499"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="218"/>
                <participants group_id="P2" count="425"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="74"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did Not Meet Entrance Criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set (FAS) included all participants who were randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received placebo matched to Bococizumab (PF-04950615) subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Bococizumab (PF-04950615) 150 Milligram (mg)</title>
          <description>Participants received PF-04950615 150 mg subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="247"/>
            <count group_id="B2" value="499"/>
            <count group_id="B3" value="746"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.7" spread="10.0"/>
                    <measurement group_id="B2" value="61.5" spread="9.9"/>
                    <measurement group_id="B3" value="61.6" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="223"/>
                    <measurement group_id="B3" value="330"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="276"/>
                    <measurement group_id="B3" value="416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 12</title>
        <time_frame>Baseline, Week 12</time_frame>
        <population>FAS included all participants who were randomized. Here, &quot;Number of participants analyzed (N)&quot; signifies number of participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to Bococizumab (PF-04950615) subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Bococizumab (PF-04950615) 150 Milligram (mg)</title>
            <description>Participants received PF-04950615 150 mg subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 12</title>
          <population>FAS included all participants who were randomized. Here, &quot;Number of participants analyzed (N)&quot; signifies number of participants who were evaluable for this outcome measure.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="17.61"/>
                    <measurement group_id="O2" value="-50.8" spread="29.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Least square (LS) mean difference and associated 95% confidence interval (CI), and p-value were derived from an mixed effect model repeat measurement (MMRM) model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>-49.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-54.0</ci_lower_limit>
            <ci_upper_limit>-45.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Fasting Total Cholesterol (TC) at Week 12, 24 and 52</title>
        <time_frame>Baseline, Week 12, 24, 52</time_frame>
        <population>FAS included all participants who were randomized. Here, &quot;n&quot; signifies number of participants who were evaluable at the specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to Bococizumab (PF-04950615) subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Bococizumab (PF-04950615) 150 Milligram (mg)</title>
            <description>Participants received PF-04950615 150 mg subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Fasting Total Cholesterol (TC) at Week 12, 24 and 52</title>
          <population>FAS included all participants who were randomized. Here, &quot;n&quot; signifies number of participants who were evaluable at the specified time points.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n =236, 469)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="13.41"/>
                    <measurement group_id="O2" value="-35.4" spread="20.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n =237, 463)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="15.79"/>
                    <measurement group_id="O2" value="-32.9" spread="23.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n =221, 425)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="17.22"/>
                    <measurement group_id="O2" value="-29.0" spread="22.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12: LS mean difference and associated 95% CI and p-value were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>-33.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.48</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-36.1</ci_lower_limit>
            <ci_upper_limit>-30.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24: LS mean difference and associated 95% CI were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>-29.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.66</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32.8</ci_lower_limit>
            <ci_upper_limit>-26.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52: LS mean difference and associated 95% CI were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>-23.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.65</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.0</ci_lower_limit>
            <ci_upper_limit>-20.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) at Week 12, 24 and 52</title>
        <time_frame>Baseline, Week 12, 24, 52</time_frame>
        <population>FAS included all participants who were randomized. Here, &quot;n&quot; signifies number of participants who were evaluable at the specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to Bococizumab (PF-04950615) subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Bococizumab (PF-04950615) 150 Milligram (mg)</title>
            <description>Participants received PF-04950615 150 mg subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) at Week 12, 24 and 52</title>
          <population>FAS included all participants who were randomized. Here, &quot;n&quot; signifies number of participants who were evaluable at the specified time points.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n =234, 467)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="16.70"/>
                    <measurement group_id="O2" value="-46.5" spread="28.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n =236, 461)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="18.66"/>
                    <measurement group_id="O2" value="-43.5" spread="32.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n =221, 425)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="20.77"/>
                    <measurement group_id="O2" value="-37.3" spread="29.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12: LS mean difference and associated 95% CI, and p-value were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>-45.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.04</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-49.7</ci_lower_limit>
            <ci_upper_limit>-41.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24: LS mean difference and associated 95% CI, were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>-40.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.26</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-45.3</ci_lower_limit>
            <ci_upper_limit>-36.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52: LS mean difference and associated 95% CI, were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>-32.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-36.7</ci_lower_limit>
            <ci_upper_limit>-28.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Fasting Non High Density Lipoprotein Cholesterol (Non HDL-C) at Week 12, 24 and 52</title>
        <time_frame>Baseline, Week 12, 24, 52</time_frame>
        <population>FAS included all participants who were randomized. Here, &quot;n&quot; signifies number of participants who were evaluable at the specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to Bococizumab (PF-04950615) subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Bococizumab (PF-04950615) 150 Milligram (mg)</title>
            <description>Participants received PF-04950615 150 mg subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Fasting Non High Density Lipoprotein Cholesterol (Non HDL-C) at Week 12, 24 and 52</title>
          <population>FAS included all participants who were randomized. Here, &quot;n&quot; signifies number of participants who were evaluable at the specified time points.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n =236, 469)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" spread="17.57"/>
                    <measurement group_id="O2" value="-47.6" spread="28.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n =237, 463)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="20.63"/>
                    <measurement group_id="O2" value="-44.7" spread="30.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n =221, 425)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.4" spread="22.70"/>
                    <measurement group_id="O2" value="-39.5" spread="29.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12: LS mean difference and associated 95% CI and p-value were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>-45.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.99</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-48.9</ci_lower_limit>
            <ci_upper_limit>-41.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>-40.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-44.8</ci_lower_limit>
            <ci_upper_limit>-36.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>-32.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-37.0</ci_lower_limit>
            <ci_upper_limit>-28.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) by Triglycerides Cut-off of Less Than (&lt;) 200 Milligram Per Deciliter (mg/dL) at Week 12, 24 and 52</title>
        <time_frame>Baseline, Week 12, 24, 52</time_frame>
        <population>A subset of FAS included all participants who were randomized and had TG &lt;200 mg/dL at pre-randomization. Here, &quot;n&quot; signifies number of participants who were evaluable at the specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to Bococizumab (PF-04950615) subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Bococizumab (PF-04950615) 150 Milligram (mg)</title>
            <description>Participants received PF-04950615 150 mg subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) by Triglycerides Cut-off of Less Than (&lt;) 200 Milligram Per Deciliter (mg/dL) at Week 12, 24 and 52</title>
          <population>A subset of FAS included all participants who were randomized and had TG &lt;200 mg/dL at pre-randomization. Here, &quot;n&quot; signifies number of participants who were evaluable at the specified time points.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="331"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n =158, 313)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="16.61"/>
                    <measurement group_id="O2" value="-51.1" spread="30.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n =159, 311)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="21.68"/>
                    <measurement group_id="O2" value="-48.4" spread="33.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n =148, 292)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" spread="24.11"/>
                    <measurement group_id="O2" value="-42.2" spread="33.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12: LS mean difference and associated 95% CI and p-value were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>-51.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.59</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-56.7</ci_lower_limit>
            <ci_upper_limit>-46.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>-46.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.94</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-52.2</ci_lower_limit>
            <ci_upper_limit>-40.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>-37.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-43.3</ci_lower_limit>
            <ci_upper_limit>-31.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) by Triglycerides Cut-off of Greater Than or Equal to (&gt;=) 200 Milligram Per Deciliter (mg/dL) at Week 12, 24 and 52</title>
        <time_frame>Baseline, Week 12, 24, 52</time_frame>
        <population>A subset of FAS included all participants who were randomized and had TG &gt;=200 mg/dL at pre-randomization. Here, &quot;n&quot; signifies number of participants evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to Bococizumab (PF-04950615) subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Bococizumab (PF-04950615) 150 Milligram (mg)</title>
            <description>Participants received PF-04950615 150 mg subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) by Triglycerides Cut-off of Greater Than or Equal to (&gt;=) 200 Milligram Per Deciliter (mg/dL) at Week 12, 24 and 52</title>
          <population>A subset of FAS included all participants who were randomized and had TG &gt;=200 mg/dL at pre-randomization. Here, &quot;n&quot; signifies number of participants evaluable at specified time points.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n =77,155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="19.34"/>
                    <measurement group_id="O2" value="-50.1" spread="28.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n =77,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.7" spread="21.67"/>
                    <measurement group_id="O2" value="-45.8" spread="33.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n =74,133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.7" spread="23.78"/>
                    <measurement group_id="O2" value="-40.9" spread="30.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12: LS mean difference and associated 95% CI and p-value were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>-46.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.59</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-53.7</ci_lower_limit>
            <ci_upper_limit>-39.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24: LS mean difference and associated 95% CI were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>-39.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-47.9</ci_lower_limit>
            <ci_upper_limit>-31.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52: LS mean difference and associated 95% CI were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>-33.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.02</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-41.3</ci_lower_limit>
            <ci_upper_limit>-25.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Fasting Lipoprotein (A) (Lp[A]) at Week 12, 24 and 52</title>
        <time_frame>Baseline, Week 12, 24, 52</time_frame>
        <population>FAS included all participants who were randomized. Here, &quot;n&quot; signifies number of participants who were evaluable at the specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to Bococizumab (PF-04950615) subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Bococizumab (PF-04950615) 150 Milligram (mg)</title>
            <description>Participants received PF-04950615 150 mg subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Fasting Lipoprotein (A) (Lp[A]) at Week 12, 24 and 52</title>
          <population>FAS included all participants who were randomized. Here, &quot;n&quot; signifies number of participants who were evaluable at the specified time points.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n =235, 469)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="54.24"/>
                    <measurement group_id="O2" value="-25.7" spread="29.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n =235, 463)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="50.52"/>
                    <measurement group_id="O2" value="-21.3" spread="34.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n =221, 425)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.9" spread="374.64"/>
                    <measurement group_id="O2" value="-21.5" spread="32.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12: LS mean difference and associated 95% CI and p-value were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>-30.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-36.9</ci_lower_limit>
            <ci_upper_limit>-24.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>-27.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.23</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-33.9</ci_lower_limit>
            <ci_upper_limit>-21.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>-49.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>18.27</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-85.2</ci_lower_limit>
            <ci_upper_limit>-13.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL-C) at Week 12, 24 and 52</title>
        <time_frame>Baseline, Week 12, 24, 52</time_frame>
        <population>FAS included all participants who were randomized. Here, &quot;n&quot; signifies number of participants who were evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to Bococizumab (PF-04950615) subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Bococizumab (PF-04950615) 150 Milligram (mg)</title>
            <description>Participants received PF-04950615 150 mg subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL-C) at Week 12, 24 and 52</title>
          <population>FAS included all participants who were randomized. Here, &quot;n&quot; signifies number of participants who were evaluable at specified time points.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n =236, 469)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="13.93"/>
                    <measurement group_id="O2" value="6.3" spread="13.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n =237, 463)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="14.88"/>
                    <measurement group_id="O2" value="6.3" spread="14.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n =221, 425)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="14.24"/>
                    <measurement group_id="O2" value="7.0" spread="15.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12: LS mean difference and associated 95% CI and p-value were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>5.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.4</ci_lower_limit>
            <ci_upper_limit>7.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>5.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.2</ci_lower_limit>
            <ci_upper_limit>7.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>6.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.6</ci_lower_limit>
            <ci_upper_limit>8.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 24 and 52</title>
        <time_frame>Baseline, Week 24, 52</time_frame>
        <population>FAS included all participants who were randomized. Here, &quot;n&quot; signifies number of participants who were evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to Bococizumab (PF-04950615) subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Bococizumab (PF-04950615) 150 Milligram (mg)</title>
            <description>Participants received PF-04950615 150 mg subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 24 and 52</title>
          <population>FAS included all participants who were randomized. Here, &quot;n&quot; signifies number of participants who were evaluable at specified time points.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24 (n =236, 461)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="21.72"/>
                    <measurement group_id="O2" value="-47.5" spread="33.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n =222, 425)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.7" spread="23.96"/>
                    <measurement group_id="O2" value="-41.8" spread="32.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>-44.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.39</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-48.8</ci_lower_limit>
            <ci_upper_limit>-39.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>-36.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.42</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-40.9</ci_lower_limit>
            <ci_upper_limit>-31.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Fasting Triglycerides (TG) at Week 12, 24 and 52</title>
        <time_frame>Baseline, Week 12, 24, 52</time_frame>
        <population>FAS included all participants who were randomized. Here, &quot;n&quot; signifies number of participants who were evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to Bococizumab (PF-04950615) subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Bococizumab (PF-04950615) 150 Milligram (mg)</title>
            <description>Participants received PF-04950615 150 mg subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Fasting Triglycerides (TG) at Week 12, 24 and 52</title>
          <population>FAS included all participants who were randomized. Here, &quot;n&quot; signifies number of participants who were evaluable at specified time points.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n =236, 469)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.2" spread="32.92"/>
                    <measurement group_id="O2" value="-16.2" spread="32.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n =237, 463)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.9" spread="35.60"/>
                    <measurement group_id="O2" value="-18.2" spread="65.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n =221, 425)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.0" spread="41.46"/>
                    <measurement group_id="O2" value="-15.8" spread="35.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>-10.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.55</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-15.1</ci_lower_limit>
            <ci_upper_limit>-5.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>-9.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.50</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-17.9</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>-8.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.04</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-14.1</ci_lower_limit>
            <ci_upper_limit>-2.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Fasting Apolipoprotein A-I (ApoA-I) at Week 12, 24 and 52</title>
        <time_frame>Baseline, Week 12, 24, 52</time_frame>
        <population>FAS included all participants who were randomized. Here, &quot;n&quot; signifies number of participants who were evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to Bococizumab (PF-04950615) subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Bococizumab (PF-04950615) 150 Milligram (mg)</title>
            <description>Participants received PF-04950615 150 mg subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Fasting Apolipoprotein A-I (ApoA-I) at Week 12, 24 and 52</title>
          <population>FAS included all participants who were randomized. Here, &quot;n&quot; signifies number of participants who were evaluable at specified time points.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n =236, 468)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="11.09"/>
                    <measurement group_id="O2" value="3.4" spread="11.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n =236, 461)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="10.81"/>
                    <measurement group_id="O2" value="2.5" spread="11.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n =221, 425)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="13.12"/>
                    <measurement group_id="O2" value="3.4" spread="11.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>4.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.85</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.5</ci_lower_limit>
            <ci_upper_limit>5.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>3.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.86</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.2</ci_lower_limit>
            <ci_upper_limit>5.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>4.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.97</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.4</ci_lower_limit>
            <ci_upper_limit>6.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Fasting Apolipoprotein A-II (ApoA-II) at Week 12, 24 and 52</title>
        <time_frame>Baseline, Week 12, 24, 52</time_frame>
        <population>FAS included all participants who were randomized. Here, &quot;n&quot; signifies number of participants who were evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to Bococizumab (PF-04950615) subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Bococizumab (PF-04950615) 150 Milligram (mg)</title>
            <description>Participants received PF-04950615 150 mg subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Fasting Apolipoprotein A-II (ApoA-II) at Week 12, 24 and 52</title>
          <population>FAS included all participants who were randomized. Here, &quot;n&quot; signifies number of participants who were evaluable at specified time points.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n =235, 468)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="11.94"/>
                    <measurement group_id="O2" value="3.0" spread="11.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n =233, 462)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="12.12"/>
                    <measurement group_id="O2" value="3.7" spread="14.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n =220, 423)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="12.46"/>
                    <measurement group_id="O2" value="1.9" spread="12.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>1.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.90</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>2.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>0.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.04</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>0.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.95</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>2.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Fasting Very Low Density Lipoprotein Cholesterol (VLDL-C) at Week 12, 24 and 52</title>
        <time_frame>Baseline, Week 12, 24, 52</time_frame>
        <population>FAS included all participants who were randomized. Here, &quot;n&quot; signifies number of participants who were evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to Bococizumab (PF-04950615) subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Bococizumab (PF-04950615) 150 Milligram (mg)</title>
            <description>Participants received PF-04950615 150 mg subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Fasting Very Low Density Lipoprotein Cholesterol (VLDL-C) at Week 12, 24 and 52</title>
          <population>FAS included all participants who were randomized. Here, &quot;n&quot; signifies number of participants who were evaluable at specified time points.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n =236, 469)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.2" spread="32.92"/>
                    <measurement group_id="O2" value="-16.2" spread="32.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n =237, 463)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.9" spread="35.60"/>
                    <measurement group_id="O2" value="-18.2" spread="65.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n =221, 425)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.0" spread="41.46"/>
                    <measurement group_id="O2" value="-15.8" spread="35.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>-10.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.55</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-15.1</ci_lower_limit>
            <ci_upper_limit>-5.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>-9.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.50</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-17.9</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>-8.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.04</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-14.1</ci_lower_limit>
            <ci_upper_limit>-2.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) by Triglycerides Cut-off of Less Than (&lt;) 200 Milligram Per Deciliter (mg/dL) at Week 12</title>
        <time_frame>Baseline, Week 12</time_frame>
        <population>A subset of FAS included all participants who were randomized and had TG &lt;200 mg/dL at pre-randomization. Here, &quot;n&quot; signifies number of participants evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to Bococizumab (PF-04950615) subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Bococizumab (PF-04950615) 150 Milligram (mg)</title>
            <description>Participants received PF-04950615 150 mg subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) by Triglycerides Cut-off of Less Than (&lt;) 200 Milligram Per Deciliter (mg/dL) at Week 12</title>
          <population>A subset of FAS included all participants who were randomized and had TG &lt;200 mg/dL at pre-randomization. Here, &quot;n&quot; signifies number of participants evaluable at specified time points.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="331"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n =164, 331)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.1" spread="25.22"/>
                    <measurement group_id="O2" value="130.2" spread="28.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12 (n =158, 313)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="22.37"/>
                    <measurement group_id="O2" value="-67.3" spread="40.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>-66.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-73.0</ci_lower_limit>
            <ci_upper_limit>-60.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) by Triglycerides Cut-off of Greater Than or Equal to (&gt;=) 200 Milligram Per Deciliter (mg/dL) at Week 12</title>
        <time_frame>Baseline, Week 12</time_frame>
        <population>A subset of FAS included all participants who were randomized and had TG &gt;=200 mg/dL at pre-randomization. Here, &quot;n&quot; signifies number of participants evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to Bococizumab (PF-04950615) subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Bococizumab (PF-04950615) 150 Milligram (mg)</title>
            <description>Participants received PF-04950615 150 mg subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) by Triglycerides Cut-off of Greater Than or Equal to (&gt;=) 200 Milligram Per Deciliter (mg/dL) at Week 12</title>
          <population>A subset of FAS included all participants who were randomized and had TG &gt;=200 mg/dL at pre-randomization. Here, &quot;n&quot; signifies number of participants evaluable at specified time points.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n =83, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.7" spread="35.49"/>
                    <measurement group_id="O2" value="147.2" spread="39.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12 (n =77, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.6" spread="29.61"/>
                    <measurement group_id="O2" value="-74.1" spread="48.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>-66.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.40</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-76.7</ci_lower_limit>
            <ci_upper_limit>-55.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 12</title>
        <time_frame>Baseline, Week 12</time_frame>
        <population>FAS included all participants who were randomized. Here, &quot;n&quot; signifies number of participants who were evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to Bococizumab (PF-04950615) subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Bococizumab (PF-04950615) 150 Milligram (mg)</title>
            <description>Participants received PF-04950615 150 mg subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 12</title>
          <population>FAS included all participants who were randomized. Here, &quot;n&quot; signifies number of participants who were evaluable at specified time points.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n =247, 499)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.7" spread="29.71"/>
                    <measurement group_id="O2" value="135.9" spread="33.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12 (n =235, 468)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="25.07"/>
                    <measurement group_id="O2" value="-69.6" spread="42.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>-66.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.77</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-72.0</ci_lower_limit>
            <ci_upper_limit>-61.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Fasting Total Cholesterol (TC) at Week 12</title>
        <time_frame>Baseline, Week 12</time_frame>
        <population>FAS included all participants who were randomized. Here, &quot;n&quot; signifies number of participants who were evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to Bococizumab (PF-04950615) subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Bococizumab (PF-04950615) 150 Milligram (mg)</title>
            <description>Participants received PF-04950615 150 mg subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Fasting Total Cholesterol (TC) at Week 12</title>
          <population>FAS included all participants who were randomized. Here, &quot;n&quot; signifies number of participants who were evaluable at specified time points.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n =247, 499)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209.4" spread="33.84"/>
                    <measurement group_id="O2" value="210.3" spread="37.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12 (n =236, 469)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.9" spread="29.61"/>
                    <measurement group_id="O2" value="-75.4" spread="46.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>-69.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-75.2</ci_lower_limit>
            <ci_upper_limit>-63.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Fasting Non High Density Lipoprotein Cholesterol (Non HDL-C) at Week 12</title>
        <time_frame>Baseline, Week 12</time_frame>
        <population>FAS included all participants who were randomized. Here, &quot;n&quot; signifies number of participants who were evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to Bococizumab (PF-04950615) subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Bococizumab (PF-04950615) 150 Milligram (mg)</title>
            <description>Participants received PF-04950615 150 mg subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Fasting Non High Density Lipoprotein Cholesterol (Non HDL-C) at Week 12</title>
          <population>FAS included all participants who were randomized. Here, &quot;n&quot; signifies number of participants who were evaluable at specified time points.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n =247, 499)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160.2" spread="33.49"/>
                    <measurement group_id="O2" value="162.1" spread="37.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12 (n =236, 469)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.8" spread="29.59"/>
                    <measurement group_id="O2" value="-77.9" spread="48.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>-71.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-77.5</ci_lower_limit>
            <ci_upper_limit>-65.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Fasting Apolipoprotein B (ApoB) at Week 12</title>
        <time_frame>Baseline, Week 12</time_frame>
        <population>FAS included all participants who were randomized. Here, &quot;n&quot; signifies number of participants who were evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to Bococizumab (PF-04950615) subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Bococizumab (PF-04950615) 150 Milligram (mg)</title>
            <description>Participants received PF-04950615 150 mg subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Fasting Apolipoprotein B (ApoB) at Week 12</title>
          <population>FAS included all participants who were randomized. Here, &quot;n&quot; signifies number of participants who were evaluable at specified time points.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n =247, 499)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.1" spread="20.43"/>
                    <measurement group_id="O2" value="107.1" spread="23.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12 (n =234, 467)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="18.09"/>
                    <measurement group_id="O2" value="-49.8" spread="31.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>-47.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-51.9</ci_lower_limit>
            <ci_upper_limit>-43.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Fasting Lipoprotein (A) (Lp[A]) at Week 12</title>
        <time_frame>Baseline, Week 12</time_frame>
        <population>FAS included all participants who were randomized. Here, &quot;n&quot; signifies number of participants who were evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to Bococizumab (PF-04950615) subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Bococizumab (PF-04950615) 150 Milligram (mg)</title>
            <description>Participants received PF-04950615 150 mg subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Fasting Lipoprotein (A) (Lp[A]) at Week 12</title>
          <population>FAS included all participants who were randomized. Here, &quot;n&quot; signifies number of participants who were evaluable at specified time points.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n =247, 499)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.5" spread="54.04"/>
                    <measurement group_id="O2" value="47.3" spread="53.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12 (n =235, 469)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="10.91"/>
                    <measurement group_id="O2" value="-10.3" spread="17.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>-10.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-12.5</ci_lower_limit>
            <ci_upper_limit>-8.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL-C) at Week 12</title>
        <time_frame>Baseline, Week 12</time_frame>
        <population>FAS included all participants who were randomized. Here, &quot;n&quot; signifies number of participants who were evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to Bococizumab (PF-04950615) subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Bococizumab (PF-04950615) 150 Milligram (mg)</title>
            <description>Participants received PF-04950615 150 mg subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL-C) at Week 12</title>
          <population>FAS included all participants who were randomized. Here, &quot;n&quot; signifies number of participants who were evaluable at specified time points.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n =247, 499)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.2" spread="13.20"/>
                    <measurement group_id="O2" value="48.3" spread="11.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12 (n =236, 469)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="6.75"/>
                    <measurement group_id="O2" value="2.5" spread="6.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>2.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.52</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.6</ci_lower_limit>
            <ci_upper_limit>3.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Ratio of Fasting Total Cholesterol (TC) to High Density Lipoprotein Cholesterol (HDL-C) at Week 12, 24 and 52</title>
        <time_frame>Baseline, Week 12, 24, 52</time_frame>
        <population>FAS included all participants who were randomized. Here, &quot;n&quot; signifies number of participants who were evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to Bococizumab (PF-04950615) subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Bococizumab (PF-04950615) 150 Milligram (mg)</title>
            <description>Participants received PF-04950615 150 mg subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Ratio of Fasting Total Cholesterol (TC) to High Density Lipoprotein Cholesterol (HDL-C) at Week 12, 24 and 52</title>
          <population>FAS included all participants who were randomized. Here, &quot;n&quot; signifies number of participants who were evaluable at specified time points.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n =247, 499)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="1.90"/>
                    <measurement group_id="O2" value="4.6" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12 (n =236, 469)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="1.27"/>
                    <measurement group_id="O2" value="-1.8" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24 (n =237, 463)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="1.42"/>
                    <measurement group_id="O2" value="-1.6" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 52 (n =221, 425)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="1.62"/>
                    <measurement group_id="O2" value="-1.5" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>-1.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>-1.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>-1.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>-1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>-1.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>-1.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Ratio of Fasting Apolipoprotein B (ApoB) to Apolipoprotein A-I (ApoA-I) at Week 12, 24 and 52</title>
        <time_frame>Baseline, Week 12, 24, 52</time_frame>
        <population>FAS included all participants who were randomized. Here, &quot;n&quot; signifies number of participants evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to Bococizumab (PF-04950615) subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Bococizumab (PF-04950615) 150 Milligram (mg)</title>
            <description>Participants received PF-04950615 150 mg subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Ratio of Fasting Apolipoprotein B (ApoB) to Apolipoprotein A-I (ApoA-I) at Week 12, 24 and 52</title>
          <population>FAS included all participants who were randomized. Here, &quot;n&quot; signifies number of participants evaluable at specified time points.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n =247, 499)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.25"/>
                    <measurement group_id="O2" value="0.8" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12 (n =234, 467)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.14"/>
                    <measurement group_id="O2" value="-0.4" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24 (n =236, 461)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0" spread="0.16"/>
                    <measurement group_id="O2" value="-0.3" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 52 (n =221, 425)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.66"/>
                    <measurement group_id="O2" value="-0.3" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12: LS mean difference and associated 95% confidence interval CI were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>-0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.02</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>-0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24: LS mean difference and associated 95% confidence interval CI were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>-0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.02</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>-0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52: LS mean difference and associated 95% confidence interval CI were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS mean difference compared to placebo</param_type>
            <param_value>-0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.04</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Fasting Low Density Lipoprotein Cholesterol (LDL-C) Less Than or Equal to (&lt;=) 100 Milligram Per Deciliter (mg/dL) at Week 12, 24 and 52</title>
        <time_frame>Week 12, 24, 52</time_frame>
        <population>FAS included all participants who were randomized. Here, n signifies those participants who were evaluable at specified time points for each arm respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to Bococizumab (PF-04950615) subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Bococizumab (PF-04950615) 150 Milligram (mg)</title>
            <description>Participants received PF-04950615 150 mg subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Fasting Low Density Lipoprotein Cholesterol (LDL-C) Less Than or Equal to (&lt;=) 100 Milligram Per Deciliter (mg/dL) at Week 12, 24 and 52</title>
          <population>FAS included all participants who were randomized. Here, n signifies those participants who were evaluable at specified time points for each arm respectively.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n =235, 468)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2"/>
                    <measurement group_id="O2" value="81.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n =236, 461)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.9"/>
                    <measurement group_id="O2" value="75.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n =222, 425)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.2"/>
                    <measurement group_id="O2" value="72.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12: Odds ratio, associated 95% CI were derived from a logistic regression model with fixed effects for treatment group, baseline value, geographical region and triglyceride subgroup.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>53.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>32.08</ci_lower_limit>
            <ci_upper_limit>90.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24: Odds ratio, associated 95% CI were derived from a logistic regression model with fixed effects for treatment group, baseline value, geographical region and triglyceride subgroup.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>17.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>11.15</ci_lower_limit>
            <ci_upper_limit>26.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52: Odds ratio, associated 95% CI were derived from a logistic regression model with fixed effects for treatment group, baseline value, geographical region and triglyceride subgroup.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>9.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>6.18</ci_lower_limit>
            <ci_upper_limit>13.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Fasting Low Density Lipoprotein Cholesterol (LDL-C) Less Than or Equal to (&lt;=) 70 Milligram Per Deciliter (mg/dL) at Week 12, 24 and 52</title>
        <time_frame>Week 12, 24, 52</time_frame>
        <population>FAS included all participants who were randomized. Here, n signifies those participants who were evaluable at specified time points for each arm respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to Bococizumab (PF-04950615) subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Bococizumab (PF-04950615) 150 Milligram (mg)</title>
            <description>Participants received PF-04950615 150 mg subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Fasting Low Density Lipoprotein Cholesterol (LDL-C) Less Than or Equal to (&lt;=) 70 Milligram Per Deciliter (mg/dL) at Week 12, 24 and 52</title>
          <population>FAS included all participants who were randomized. Here, n signifies those participants who were evaluable at specified time points for each arm respectively.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n =235, 468)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="62.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n =236, 461)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="60.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n = 222, 425)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2"/>
                    <measurement group_id="O2" value="53.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12: Odds ratio, associated 95% CI were derived from a logistic regression model with fixed effects for treatment group, baseline value, geographical region and triglyceride subgroup.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>156.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>48.84</ci_lower_limit>
            <ci_upper_limit>501.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24: Odds ratio, associated 95% CI were derived from a logistic regression model with fixed effects for treatment group, baseline value, geographical region and triglyceride subgroup.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>110.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>39.77</ci_lower_limit>
            <ci_upper_limit>308.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52: Odds ratio, associated 95% CI were derived from a logistic regression model with fixed effects for treatment group, baseline value, geographical region and triglyceride subgroup.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>43.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>19.52</ci_lower_limit>
            <ci_upper_limit>96.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration Versus Time Summary of PF-04950615</title>
        <time_frame>Week 12, 24, 52</time_frame>
        <population>Analysis set included participants who received at least 1 dose of PF-04950615. This outcome measure was planned not to be analysed for placebo reporting arm. Here, &quot;n&quot; signifies those participants who were evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Bococizumab (PF-04950615) 150 Milligram (mg)</title>
            <description>Participants received PF-04950615 150 mg subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration Versus Time Summary of PF-04950615</title>
          <population>Analysis set included participants who received at least 1 dose of PF-04950615. This outcome measure was planned not to be analysed for placebo reporting arm. Here, &quot;n&quot; signifies those participants who were evaluable at specified time points.</population>
          <units>microgram per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n =456)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.37" spread="5.327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n =448)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.28" spread="5.888"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n =418)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.01" spread="4.652"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Adverse Events (AEs) Related to Type 1 and 3 Hypersensitivity Reactions and Injection Site Reactions</title>
        <description>Type 1 hypersensitivity or allergic reactions were possible in response to any injected protein and included shortness of breath, urticaria, anaphylaxis and angioedema. Type 3 hypersensitivity reactions were similar to Type 1 hypersensitivity reactions but were likely to be delayed from the time of injection and included symptoms such as rash, urticaria, polyarthritis, myalgias, polysynovitis, fever and if severe then included glomerulonephritis. Injection site reactions included injection site bruising, discolouration, erythema, haematoma, haemorrhage, nodule, induration, inflammation, mass, pain, paraesthesia, pruritus, swelling, vesicles, warmth, scab and rash. Participants with type 1 or type 3 hypersensitivity reactions and participants with injection site reactions were reported in this outcome measure.</description>
        <time_frame>Baseline up to end of study (up to 58 weeks)</time_frame>
        <population>Safety analysis set included all participants who received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to Bococizumab (PF-04950615) subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Bococizumab (PF-04950615) 150 Milligram (mg)</title>
            <description>Participants received PF-04950615 150 mg subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events (AEs) Related to Type 1 and 3 Hypersensitivity Reactions and Injection Site Reactions</title>
          <description>Type 1 hypersensitivity or allergic reactions were possible in response to any injected protein and included shortness of breath, urticaria, anaphylaxis and angioedema. Type 3 hypersensitivity reactions were similar to Type 1 hypersensitivity reactions but were likely to be delayed from the time of injection and included symptoms such as rash, urticaria, polyarthritis, myalgias, polysynovitis, fever and if severe then included glomerulonephritis. Injection site reactions included injection site bruising, discolouration, erythema, haematoma, haemorrhage, nodule, induration, inflammation, mass, pain, paraesthesia, pruritus, swelling, vesicles, warmth, scab and rash. Participants with type 1 or type 3 hypersensitivity reactions and participants with injection site reactions were reported in this outcome measure.</description>
          <population>Safety analysis set included all participants who received at least 1 dose of study treatment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With type 1 or 3 hypersensitivity reactions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With injection site reactions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Positive Anti-drug Antibodies (ADA) of PF-04950615</title>
        <description>Percentage of participants with at least 1 positive ADA titer were reported. Participants with their ADA titer &gt;=6.23 were considered to be ADA positive.</description>
        <time_frame>Baseline up to end of study (up to 58 weeks)</time_frame>
        <population>Analysis set included all participants who received at least 1 dose of PF-04950615 150 mg. This outcome measure was planned not to be analysed for placebo reporting arm. Here &quot;N&quot; signifies number of participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Bococizumab (PF-04950615) 150 Milligram (mg)</title>
            <description>Participants received PF-04950615 150 mg subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Positive Anti-drug Antibodies (ADA) of PF-04950615</title>
          <description>Percentage of participants with at least 1 positive ADA titer were reported. Participants with their ADA titer &gt;=6.23 were considered to be ADA positive.</description>
          <population>Analysis set included all participants who received at least 1 dose of PF-04950615 150 mg. This outcome measure was planned not to be analysed for placebo reporting arm. Here &quot;N&quot; signifies number of participants who were evaluable for this outcome measure.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="491"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to end of study (up to 58 weeks)</time_frame>
      <desc>Same event may appear as AE and serious AE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received placebo matched to Bococizumab (PF-04950615) subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Bococizumab (PF-04950615) 150 Milligram (mg)</title>
          <description>Participants received PF-04950615 150 mg subcutaneous injection once in every 2 weeks up to Week 52. Participants were followed up to 58 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Oesophageal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>POSSIBLE SEIZURE DISORDER SECONDARY TO AMPHETAMINE ABUSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Complication associated with device</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Vascular stent occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arterial injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Spondyloarthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Bone cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Breast cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Tonsil cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Miller Fisher syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Depression suicidal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Paranoia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Psychiatric decompensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Suicidal behaviour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Peripheral artery dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="499"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

